Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Orthofix Medical (OFIX) Other Non-Current Assets (2016 - 2025)

Orthofix Medical's Other Non-Current Assets history spans 16 years, with the latest figure at $36.7 million for Q4 2025.

  • For the quarter ending Q4 2025, Other Non-Current Assets rose 1368.08% year-over-year to $36.7 million, compared with a TTM value of $36.7 million through Dec 2025, up 1368.08%, and an annual FY2025 reading of $36.7 million, up 1368.08% over the prior year.
  • Other Non-Current Assets for Q4 2025 was $36.7 million at Orthofix Medical, down from $37.8 million in the prior quarter.
  • The five-year high for Other Non-Current Assets was $45.4 million in Q1 2023, with the low at $488000.0 in Q1 2021.
  • Average Other Non-Current Assets over 5 years is $19.6 million, with a median of $22.2 million recorded in 2021.
  • Year-over-year, Other Non-Current Assets skyrocketed 5014.55% in 2022 and then plummeted 94.5% in 2024.
  • Tracing OFIX's Other Non-Current Assets over 5 years: stood at $23.9 million in 2021, then rose by 7.71% to $25.7 million in 2022, then plummeted by 81.91% to $4.6 million in 2023, then tumbled by 46.24% to $2.5 million in 2024, then skyrocketed by 1368.08% to $36.7 million in 2025.
  • Per Business Quant, the three most recent readings for OFIX's Other Non-Current Assets are $36.7 million (Q4 2025), $37.8 million (Q3 2025), and $3.1 million (Q2 2025).